Academic literature on the topic 'Adoptive cell therapy, telomerase, leukemia'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Contents
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Adoptive cell therapy, telomerase, leukemia.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Adoptive cell therapy, telomerase, leukemia"
Sandri, Sara, Sara Bobisse, Kelly Moxley, Alessia Lamolinara, Francesco De Sanctis, Federico Boschi, Andrea Sbarbati, et al. "Feasibility of Telomerase-Specific Adoptive T-cell Therapy for B-cell Chronic Lymphocytic Leukemia and Solid Malignancies." Cancer Research 76, no. 9 (May 1, 2016): 2540–51. http://dx.doi.org/10.1158/0008-5472.can-15-2318.
Full textJanelle, Valérie, Mathieu Neault, Marie-Eve Lebel, Dave De Sousa, Salix Boulet, Ludovic Durrieu, Cedric Carli, et al. "516 Caspase-8 regulated senescence as an immune checkpoint in T lymphocytes for adoptive cell therapy." Journal for ImmunoTherapy of Cancer 8, Suppl 3 (November 2020): A552. http://dx.doi.org/10.1136/jitc-2020-sitc2020.0516.
Full textTanimoto, Kazushi, Hiroshi Fujiwara, Hiroki Tanaka, Fumihiro Ochi, Hiroaki Asai, Sachiko Okamoto, Junichi Mineno, et al. "Concomitant Administration of Gene-Modified T Cells Expressing a Chimeric CD16-CD3ζ Receptor with Mogamulizmab Synergistically Suppresses Adult T Cell Leukemia Cells in Vivo." Blood 124, no. 21 (December 6, 2014): 307. http://dx.doi.org/10.1182/blood.v124.21.307.307.
Full textBankoti, Rashmi, Hazal Pektas Akbal, Maddalena Adorno, and Benedetta Di Robilant. "830 Targeting cellular senescence to increase CAR-T cell fitness." Journal for ImmunoTherapy of Cancer 8, Suppl 3 (November 2020): A882. http://dx.doi.org/10.1136/jitc-2020-sitc2020.0830.
Full textGarber, Haven R., Asma Mirza, Elizabeth A. Mittendorf, and Gheath Alatrash. "Adoptive T-cell therapy for Leukemia." Molecular and Cellular Therapies 2, no. 1 (2014): 25. http://dx.doi.org/10.1186/2052-8426-2-25.
Full textCalado, Rodrigo T. "Targeting telomerase: T-cell friendly fire." Blood 115, no. 7 (February 18, 2010): 1316. http://dx.doi.org/10.1182/blood-2009-12-254961.
Full textMa, Hongbing, Swaminathan Padmanabhan Iyer, Simrit Parmar, and Yuping Gong. "Adoptive cell therapy for acute myeloid leukemia." Leukemia & Lymphoma 60, no. 6 (January 10, 2019): 1370–80. http://dx.doi.org/10.1080/10428194.2018.1553300.
Full textUgel, Stefano, Elisa Scarselli, Manuela Iezzi, Carmela Mennuni, Tania Pannellini, Francesco Calvaruso, Barbara Cipriani, et al. "Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes." Blood 115, no. 7 (February 18, 2010): 1374–84. http://dx.doi.org/10.1182/blood-2009-07-233270.
Full textLulla, Premal D., Maksim Mamonkin, and Malcolm K. Brenner. "Adoptive Cell Therapy for Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia." Cancer Journal 25, no. 3 (2019): 199–207. http://dx.doi.org/10.1097/ppo.0000000000000376.
Full textMiyazaki, Yukihiro, Hiroshi Fujiwara, Hiroaki Asai, Fumihiro Ochi, Toshiki Ochi, Taichi Azuma, Takashi Ishida, et al. "Development of a novel redirected T-cell–based adoptive immunotherapy targeting human telomerase reverse transcriptase for adult T-cell leukemia." Blood 121, no. 24 (June 13, 2013): 4894–901. http://dx.doi.org/10.1182/blood-2012-11-465971.
Full textDissertations / Theses on the topic "Adoptive cell therapy, telomerase, leukemia"
Ibach, Tabea [Verfasser]. "Adoptive T-cell Therapy via Chimeric Antigen Receptors (CARs) against Leukemia in Combination with a human Suicide Gene / Tabea Ibach." Düsseldorf : Universitäts- und Landesbibliothek der Heinrich-Heine-Universität Düsseldorf, 2020. http://d-nb.info/1209354136/34.
Full textAichelin, Katharina [Verfasser], and Peter [Akademischer Betreuer] Angel. "Development of a CD22-specific chimeric antigen receptor (CAR) for the adoptive T cell therapy of leukemia and lymphoma / Katharina Aichelin ; Betreuer: Peter Angel." Heidelberg : Universitätsbibliothek Heidelberg, 2020. http://d-nb.info/1211090434/34.
Full textPopović, Jelena [Verfasser]. "Suitability of the TEL-AML1 chromosomal translocation for targeting by adoptive T cell therapy of leukemia : an investigation in a novel humanized mouse model / Jelena Popović." Berlin : Freie Universität Berlin, 2011. http://d-nb.info/1029847193/34.
Full textSandri, Sara. "Targeting telomerase in b-cell chronic lymphocytic leukemia." Doctoral thesis, 2015. http://hdl.handle.net/11562/925225.
Full textTelomerase reverse transcriptase (TERT) is considered a key universal tumor associated antigen, since it is overexpressed in more than 85% of tumor cells. When TERT is reactivated in tumor cells, the enzyme is processed and its antigenic peptides are presented in association with the class I molecules of the major histocompatibility complex, promoting tumor recognition by specific cytotoxic T-lymphocytes. Recently, our group demonstrated that the adoptive cell transfer of mouse TERT198-205-specific cytotoxic T-lymphocytes were able to control the progression of several transplantable tumor models but, at the same time, the repeated administration induced a temporary autoimmune depletion of B cells. We had therefore hypotized that these results could represent a promising background for the treatment of haematologic B cell malignancies, such as B-cell chronic lymphocytic leukemia. Telomerase expression and activity is generally low or absent in normal cells, except for male germline, embryonic and hematopoietic stem cells, while it is usually elevated in malignant B cells. Moreover TERT expression and functional activity is reported to directly correlate with a worst prognosis of leukemic patients. We developed a passive immunotherapeutic approach based on the adoptive transfer of specific TERT cytotoxic T-lymphocytes both in murine B cell leukemia cancer models but also in a humanized context in which immunodeficient mice were engrafted with human leukemic cells and treated with specific engineered anti h-TERT T lymphocytes. In murine setting, we took advantage of a highly aggressive B-cell malignancy derived by IgH.TE transgenic mice, which displayed common characteristics with human B-cell chronic lymphocytic leukemia. patients such as the expansion of a CD19+/CD5+ clonal cell population expressing high levels of active telomerase. mTERT198-205-specific cytotoxic T-lymphocytes could recognize these malignant B cells both in vitro and in vivo: ~70% of treated IgH.TE-derived B cell tumor-bearing mice with the adoptive transfer of mTERT specific cytotoxic T-lymphocytes achieved complete remission. Confident about these data, we translated our work hypothesis into human setting. We cloned the hTERT865-873-specific full-length rearranged TCR / genes from our previously isolated cytotoxic T-lymphocyte clone and inserted into a novel retroviral expression vector to infect naive peripheral blood mononucleated cells, creating selective hTERT865-873-specific CTLs. These cytotoxic T cells were able to recognize both immortalized B-cell malignancies and peripheral blood mononucleated cells from leukemic patients expressing hTERT865-873 in an HLA-A2-restricted manner, both in vitro and in vivo. In fact, TERT specific adoptive transfer in leukemic immune-deficient NOG mice led to a significant reduction in the spreading of neoplastic cells in secondary organs. Moreover, hTERT865-873 specific T cells controlled the engraftment of human primary B-cell chronic lymphocytic leukemia cells in humanized NOG mice, thus confirming not only the efficacy, but also the specificity and safety of our immunotherapeutic approach. These findings suggest that naturally processed hTERT865-873/HLA-A2+ complexes presented on the surface of B-malignancies are sufficiently immunogenic to be recognized by hTERT865-873-specific cytotoxic T cells. Gene-modified T cells successfully killed malignant B cell, but not normal cells and hematopoietic progenitors, in an HLA-restricted manner both in vitro and in vivo. Our experimental observations therefore support the development of a novel hTERT865-873-targeting redirected T cell-based immunotherapy for B-cell chronic lymphocytic leukemia patients, that can also be potentially translated in clinic to treat tumors with different histology.
Books on the topic "Adoptive cell therapy, telomerase, leukemia"
Faitschuk, Elena. A novel dual chain-based design of a chimeric antigen receptor (CAR) for adoptive cell therapy and an FcR-specific CAR for improved targeting of chronic lymphocytic Leukemia (CLL). Köln, 2016.
Find full text